Pancragen

What it is

Pancragen belongs to the bioregulators or cytogens, very short synthetic peptides that the Russian gerontologist Vladimir Khavinson and his colleagues have been developing for decades. Each of these peptides is assigned to an organ. For Pancragen it is the pancreas, more precisely the part that produces insulin.

The derivation of Pancragen is somewhat different from that of the brain or thymus peptides. According to a 2005 paper, Khavinson compared the amino acid sequences of hormones that stimulate insulin release and found a shared stretch of 4 amino acids. The tetrapeptide built from it was finally modified so that digestive enzymes break it down less easily. A 2014 modeling study accordingly describes it as a mimic of insulin-promoting peptides.

In the Russian literature, the substance appears under several spellings, as Pancragen, Pancragene and Pankragen. One of the human studies used a preparation called Pankragen forte, which is described in the abstract as the same tetrapeptide.

How it is supposed to work

The Khavinson school assumes that very short peptides reach the cell nucleus, bind to the DNA there and change how certain genes are read. For Pancragen the authors have worked this out specifically: according to a 2014 modeling study, it can fit into both grooves of the DNA, and the sequence GGCAG is considered a possible binding site. As early as 2005 it was suspected that it acts in this way on the promoter of the insulin precursor gene.

Findings in human cells in the culture dish fit with this. In pancreatic cells, Pancragen increased the production of differentiation factors, that is, of signals that determine whether a cell matures into an insulin-producing islet cell or a cell producing digestive enzymes. The effect was stronger in aged cultures than in young ones. Another 2012 paper found more markers of cell division and cell protection in aged pancreatic cells and less of the protein p53, which triggers programmed cell death.

From these findings the group derives the idea that Pancragen could, as it were, rejuvenate an aging pancreas. This is a coherent hypothesis with cell and animal findings. How much of it reaches the human body has not been measured.

What the studies show

Older people with type 2 diabetes, 2011

Korkushko and colleagues from the Institute of Gerontology in Kyiv, with Khavinson as co-author, studied 30 healthy older people and 33 with type 2 diabetes. In diabetes, nocturnal melatonin production was 70 percent lower. Under Pancragen, fasting glucose, glucose in the tolerance test, insulin and the insulin resistance index fell in the diabetics; in patients without Pancragen nothing changed. How many patients were treated, for how long and whether they were randomly assigned is not clear from the abstract.

Prediabetes in old age, 2013

The same group studied 150 people of different ages, including 69 aged 60 and over. Of these, 12 had impaired glucose tolerance and received Pankragen forte for 4 weeks. In 50 percent of them, glucose in the glucose tolerance test was significantly lower afterwards; the authors also report better blood lipids and vascular function. A control group is not described.

Old rhesus monkeys, 2014 and 2015

Goncharova and colleagues treated old female rhesus monkeys for 10 days. In the second study there were 9 animals aged 20 to 25 years: 5 received Pancragen, 4 the approved diabetes drug glimepiride. Both lowered fasting blood sugar. Pancragen normalized insulin and C-peptide, glimepiride lowered blood sugar more strongly and for longer.

Diabetic rats, 2005 and 2007

In rats with alloxan diabetes, the tetrapeptide partially restored insulin production. In streptozotocin diabetes, oral Pancragen clearly lowered blood sugar; injected, it normalized the adhesion of cells to the vessel wall of small intestinal vessels, while their permeability did not change. The abstracts do not state group sizes.

Where the data stop

The human data are thin. There are two studies, both small, both with Khavinson as co-author, and neither abstract mentions random assignment or blinding. The prediabetes study had no control group, and even there only half of the 12 treated people responded. Only laboratory values such as glucose, insulin and resistance indices were measured. Whether Pancragen prevents the onset of diabetes, reduces complications or saves medication has not been studied.

Breadth is also lacking. PubMed lists 10 entries on Pancragen, 9 of them with Khavinson as author; ClinicalTrials.gov lists no study. Several papers have appeared only in Russian, and two abstracts state no result at all. The monkey experiments each cover a handful of animals over 10 days. How the peptide is absorbed and distributed in humans has not been measured. This does not speak against the findings, but it makes independent replication an open task.

Status, approval and legal

In Germany and the EU, Pancragen is neither approved as a medicine nor authorized as a novel food; I could not verify a drug approval in Russia. In the West it is traded as a research peptide or bioregulator preparation, without tested purity and without being intended for humans. In sport, an unapproved substance falls under group S0 of the WADA Prohibited List 2026 and is prohibited at all times.

Safety

There are no systematic safety data in humans. The two human studies do not describe any recording of side effects in their abstracts, and toxicology or pharmacokinetics to Western standards have not been published. If the findings are correct, Pancragen lowers blood sugar; together with metformin, sulfonylureas, GLP-1 drugs or insulin, an additional reduction would be conceivable, but this has not been studied. People with diabetes should therefore not add or replace anything on their own, but discuss it with their doctor. There are no data for pregnant or breastfeeding women, children or people with cancer. On top of this come the usual gray market risks: unclear purity, deviating content, and with injected products, infections.

Sources

• Korkushko, Khavinson et al., Bull Exp Biol Med 2011 – Pancragen in older people with type 2 diabetes
• Korkushko, Chizhova, Shatilo, Khavinson, Adv Gerontol 2013 – Pankragen forte in prediabetes in old age
• Goncharova et al., Adv Gerontol 2014 – Pancragen and pancreatic function in old rhesus monkeys
• Goncharova et al., Adv Gerontol 2015 – Pancragen compared with glimepiride in old rhesus monkeys
• Khavinson, Bull Exp Biol Med 2005 – tetrapeptide and insulin production in alloxan diabetes
• Khavinson et al., Bull Exp Biol Med 2007 – Pancragen, blood sugar and capillaries in diabetic rats
• Khavinson et al., Bull Exp Biol Med 2013 – Pancragen and differentiation of aging pancreatic cells
• Khavinson et al., Adv Gerontol 2012 – tetrapeptide and functional markers of aged pancreatic cells
• Tarnovskaya, Yakutseni, Khavinson, Bull Exp Biol Med 2014 – modeling of DNA binding